MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
NovaBay Pharmaceuticals Total Current Liabilities 2011-2026 | NBY
Annual Total Current Liabilities NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.14 M | 2.84 M | 4.28 M | 4.26 M | 3.44 M | 2.83 M | 5.69 M | 3.85 M | 4.98 M | 4.32 M | 4.63 M | 3.34 M | 3.63 M | 3.17 M | 2.84 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.69 M | 1.14 M | 3.68 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Akebia Therapeutics
AKBA
|
163 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Aytu BioScience
AYTU
|
63.1 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
70.6 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.49 | 9.56 % | $ 397 M |  Britain |
 |
CTI BioPharma Corp.
CTIC
|
81.1 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.33 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
100 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | USA |
|
Forte Biosciences
FBRX
|
20.8 M | $ 26.27 | 0.38 % | $ 340 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
12.4 M | $ 3.88 | 2.11 % | $ 261 B | Britain |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |